Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 13,666 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 13,666 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $13.61, for a total transaction of $185,994.26. Following the sale, the general counsel now directly owns 21,476 shares in the company, valued at $292,288.36. This represents a 38.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Jonathan Allan also recently made the following trade(s):

• On Friday, December 6th, Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock. The stock was sold at an average price of $12.78, for a total transaction of $123,914.88.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $12.06 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $4.09 and a 1 year high of $17.58. The stock has a market cap of $638.82 million, a P/E ratio of -5.74 and a beta of 0.95. The stock has a 50-day simple moving average of $12.49 and a 200-day simple moving average of $13.65.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on STOK. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Finally, Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $20.83.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Lynx1 Capital Management LP raised its stake in Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after acquiring an additional 1,488,371 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Stoke Therapeutics during the second quarter worth about $19,835,000. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Logos Global Management LP purchased a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at about $14,186,000. Finally, Marshall Wace LLP boosted its position in shares of Stoke Therapeutics by 550.1% in the 2nd quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after purchasing an additional 982,451 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.